358 related articles for article (PubMed ID: 26927395)
1. Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs.
Daroudi R; Mirzania M; Zendehdel K
Int J Health Policy Manag; 2015 Oct; 5(2):99-105. PubMed ID: 26927395
[TBL] [Abstract][Full Text] [Related]
2. Do oncologists believe new cancer drugs offer good value?
Nadler E; Eckert B; Neumann PJ
Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830
[TBL] [Abstract][Full Text] [Related]
3. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
[TBL] [Abstract][Full Text] [Related]
4. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey.
Schrag D; Hanger M
J Clin Oncol; 2007 Jan; 25(2):233-7. PubMed ID: 17210946
[TBL] [Abstract][Full Text] [Related]
5. Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology.
Sacristán JA; Lizan L; Comellas M; Garrido P; Avendaño C; Cruz-Hernández JJ; Espinosa J; Dilla T
Adv Ther; 2016 Nov; 33(11):2059-2068. PubMed ID: 27718158
[TBL] [Abstract][Full Text] [Related]
6. The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative study.
Berry SR; Hubay S; Soibelman H; Martin DK
BMC Health Serv Res; 2007 Nov; 7():193. PubMed ID: 18042302
[TBL] [Abstract][Full Text] [Related]
7. Oncologists' Perceptions of Drug Affordability Using NCCN Evidence Blocks: Results from a National Survey.
Shah-Manek B; Wong W; Ravelo A; DiBonaventura M
J Manag Care Spec Pharm; 2018 Jun; 24(6):565-571. PubMed ID: 29451078
[TBL] [Abstract][Full Text] [Related]
8. European perspective on the costs and cost-effectiveness of cancer therapies.
Drummond MF; Mason AR
J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
[TBL] [Abstract][Full Text] [Related]
9. Cancer therapy costs influence treatment: a national survey of oncologists.
Neumann PJ; Palmer JA; Nadler E; Fang C; Ubel P
Health Aff (Millwood); 2010; 29(1):196-202. PubMed ID: 20048377
[TBL] [Abstract][Full Text] [Related]
10. Understanding patients' attitudes toward communication about the cost of cancer care.
Bullock AJ; Hofstatter EW; Yushak ML; Buss MK
J Oncol Pract; 2012 Jul; 8(4):e50-8. PubMed ID: 23180999
[TBL] [Abstract][Full Text] [Related]
11. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
12. In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival.
Ubel PA; Berry SR; Nadler E; Bell CM; Kozminski MA; Palmer JA; Evans WK; Strevel EL; Neumann PJ
Health Aff (Millwood); 2012 Apr; 31(4):709-17. PubMed ID: 22492887
[TBL] [Abstract][Full Text] [Related]
13. The reality of economics for oncologists.
Taylor D
Breast; 2017 Jun; 33():183-190. PubMed ID: 28432979
[TBL] [Abstract][Full Text] [Related]
14. The utility of cost discussions between patients with cancer and oncologists.
Zafar SY; Chino F; Ubel PA; Rushing C; Samsa G; Altomare I; Nicolla J; Schrag D; Tulsky JA; Abernethy AP; Peppercorn JM
Am J Manag Care; 2015 Sep; 21(9):607-15. PubMed ID: 26618364
[TBL] [Abstract][Full Text] [Related]
15. Seeking value as cancer drug costs soar.
Bender E
Cancer Discov; 2013 Aug; 3(8):833-4. PubMed ID: 23928760
[TBL] [Abstract][Full Text] [Related]
16. A Time-Trend Economic Analysis of Cancer Drug Trials.
Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
[TBL] [Abstract][Full Text] [Related]
17. How long and how well: oncologists' attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatments.
Kozminski MA; Neumann PJ; Nadler ES; Jankovic A; Ubel PA
Med Decis Making; 2011; 31(3):380-5. PubMed ID: 21088130
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the ASCO Value Framework for Anticancer Drugs at an Academic Medical Center.
Wilson L; Lin T; Wang L; Patel T; Tran D; Kim S; Dacey K; Yuen C; Kroon L; Brodowy B; Rodondi K
J Manag Care Spec Pharm; 2017 Feb; 23(2):163-169. PubMed ID: 28125363
[TBL] [Abstract][Full Text] [Related]
19. This is a call to oncologists for action.
Micó C; Berrocal A; Blasco A; Caballero C; Iranzo V; Lobo M; Camps C
Clin Transl Oncol; 2018 Dec; 20(12):1493-1501. PubMed ID: 29796999
[TBL] [Abstract][Full Text] [Related]
20. Cost issues in new disease-modifying treatments for advanced cancer: in-depth interviews with physicians.
de Kort SJ; Kenny N; van Dijk P; Gevers S; Richel DJ; Willems DL
Eur J Cancer; 2007 Sep; 43(13):1983-9. PubMed ID: 17616456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
